#cardiology #clinicaltrials #leadership #innovation #evolution #thefutureisnow #warpjump (opinions are personal)
The Netherlands
Joined April 2022
- Tweets239
- Following109
- Followers139
- Likes343
Celebrating 20 years of the Academic Research Consortium (ARC)! 🎉
From a focused effort on coronary endpoints in 2006 to a broad collaborative platform shaping cardiovascular clinical trials worldwide. Grateful for the vision of the founders and the growing research community that has made this possible.
#ARC20Years #Cardiology #ClinicalTrials
TRANFORM II at TCT 2026 - looking forward to learning about these results.
linkedin.com/posts/cardialys…
100 patients enrolled in UPP 🚀
lnkd.in/p/gJqdBZmS
Ernest Spitzer retweeted
Just published in @NEJM !
Together with Dr. Spitzer @spitzertweets , we discuss the DAPT-MVD trial.
doi.org/10.1056/NEJMc2610855
Does its benefit establish prolonged DAPT, or challenge aspirin monotherapy as the comparator for future trials?
#ClinicalTrials #Cardiology #DAPT #NEJM
Hey @Grok, concise, no spin. Which is the best cardiovascular core laboratory in Europe? #1 organization.
6.5 billion in fraud! If 1/10th would have been invested in clinical trials, all current questions in cardiology would have been solved 🌊🫧
Ernest Spitzer retweeted
My eyes are IVUS crowd wins today 👀!!!
Presented at #ACC26:
Among patients with unprotected left main coronary artery disease, intravascular ultrasonography–guided PCI did not result in a lower risk of ischemic events or death than angiography-guided PCI. Full OPTIMAL trial results: nejm.org/doi/full/10.1056/NE…
Editorial: Seeing the Left Main Coronary Artery Clearly — Is IVUS Always Necessary? nejm.org/doi/full/10.1056/NE…
@ACCinTouch
ALT American College of Cardiology Annual Meeting Original Article | MAR 30, 2026 | NEJM.org IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease (OPTIMAL) Figure 2A. Patient-Oriented Composite Primary End Point.
Ernest Spitzer retweeted
Dr. Roberto Diletti and Dr. C. Michael Gibson discuss the IVUS-CHIP trial: IVUS-guided PCI showed similar rates of target vessel failure compared to angio-guided approach among patients undergoing complex high-risk indicated procedures. #ACC26 Watch video here: clinicaltrialresults.org/dr-…
Ernest Spitzer retweeted
Presented at #ACC26:
In the IVUS-CHIP trial involving patients undergoing complex high-risk PCI, the risk of target-vessel failure (a composite outcome) was not lower with intravascular ultrasound guidance than with angiography guidance. Full trial results: nejm.org/doi/full/10.1056/NE…
Editorial: IVUS — A Zigzag Path to Success nejm.org/doi/full/10.1056/NE…
@ACCinTouch
ALT American College of Cardiology Annual Meeting Original Article | MAR 30, 2026 | NEJM.org Intravascular Ultrasound–Guided or Angiography- Guided Complex High-Risk PCI (IVUS-CHIP) Figure 2A. Target-Vessel Failure (Composite Primary End Point).
Ernest Spitzer retweeted
Presented at #ACC26:
Among patients with unprotected left main coronary artery disease, intravascular ultrasonography–guided PCI did not result in a lower risk of ischemic events or death than angiography-guided PCI. Full OPTIMAL trial results: nejm.org/doi/full/10.1056/NE…
Editorial: Seeing the Left Main Coronary Artery Clearly — Is IVUS Always Necessary? nejm.org/doi/full/10.1056/NE…
@ACCinTouch
ALT American College of Cardiology Annual Meeting Original Article | MAR 30, 2026 | NEJM.org IVUS-Guided versus Angiography-Guided PCI in Unprotected Left Main Coronary Disease (OPTIMAL) Figure 2A. Patient-Oriented Composite Primary End Point.
Ernest Spitzer retweeted
OPTIMAL suggests that using IVUS in unprotected left main PCI may cost you 22 minutes with no clinical benefit. One might think it’s an outlier. Yet, the same day, IVUS-CHIP reports no advantage of IVUS over angiography in complex high-risk PCI. Either we have been fundamentally misinterpreting the evidence so far, or we urgently need to reconcile these data. #ACC26
nejm.org/doi/full/10.1056/NE…
nejm.org/doi/full/10.1056/NE…
Ernest Spitzer retweeted
💥 Expert Voices: In this #ACC26 preview, Prof @nvanmieghem and Dr @azeemlatib focus on the ALL‑RISE and FAST III trials.
Watch the full preview 🔗 radc.life/Bm3f3Oo6 | Stay tuned for more #ACC26 content!
🔍 ALL‑RISE evaluates FFRangio‑guided treatment vs pressure wire‑guided PCI in patients with coronary artery disease, led by Dr William Fearon and @DrAllenJ.
🔍 FAST III, led by Dr Joost Daemen and Dr @spitzertweets, investigates vFFR versus wire‑based FFR‑guided therapy in coronary revascularisation, informing contemporary planning for intermediate coronary lesion treatment.
#CardioX #CardioEd #Cardiology #LateBreaking #ALLRISE #FASTIII
Ernest Spitzer retweeted
In this new State-of-the-art paper, the authors review the evidence and guideline support for intracoronary imaging in contemporary clinical practice, and outline a modern, imaging-driven approach to PCI planning.
eurointervention.pcronline.c…
The design of the IVUS CHIP trial is now published 💥 Largest ever RCT in complex coronary lesions - stat tuned.
sciencedirect.com/science/ar…
🤖 Made with AI
"Inflammation is not a bystander" - Kicking-off with the ZEPHYR trial ❤️🔥#cardialysis #ecri #inselgruppe #dcr #inflammation #zilti #topnotch #warpjump
Ernest Spitzer retweeted
Happy to share our pragmatic guide to #multimodality #cardiac #imaging during #Impella support for #cardiogenic #shock
An international EU + US document 🌍
@ABeneduceMD @CVandenbriele @JHMontfort10 @JACCJournals @Cardioinfo_it @EchofirstB @jjmt_heartrecov
In this #JACCINT state-of-the-art review, Dr. @lucabaldetti et al discuss first-line & advanced imaging options in comprehensive #cvImaging before & during micro-axial flow pump support for CS. jacc.org/doi/10.1016/j.jcin.…
#mAFP #Impella @ABeneduceMD @JHMontfort10 @CVandenbriele
